Real-World Healthcare Cost Savings and Reduced Relapse Rate With Off-Label Rituximab vs Disease-Modifying Treatments Approved for Relapsing-Remitting MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study
Ann. Neurol 2024 Mar 26;[EPub Ahead of Print], P Alping, M Neovius, F Piehl, T FrisellFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.